Gene Therapy for Heart Failure

作者：Tilemann Lisa; Ishikawa Kiyotake; Weber Thomas; Hajjar Roger J^*

来源：Circulation Research, 2012, 110(5): 777-793.

DOI：10.1161/CIRCRESAHA.111.252981

• gene therapy
• heart failure
• adeno-associated vectors

Congestive heart failure accounts for half a million deaths per year in the United States. Despite its place among the leading causes of morbidity, pharmacological and mechanic remedies have only been able to slow the progression of the disease. Today's science has yet to provide a cure, and there are few therapeutic modalities available for patients with advanced heart failure. There is a critical need to explore new therapeutic approaches in heart failure, and gene therapy has emerged as a viable alternative. Recent advances in understanding of the molecular basis of myocardial dysfunction, together with the evolution of increasingly efficient gene transfer technology, have placed heart failure within reach of gene-based therapy. The recent successful and safe completion of a phase 2 trial targeting the sarcoplasmic reticulum calcium ATPase pump (SERCA2a), along with the start of more recent phase 1 trials, opens a new era for gene therapy for the treatment of heart failure. (Circ Res. 2012;110:777-793.)

• 出版日期2012-3-2